Business
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth --ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm Insemination Prep Kit, designed to fully enable gynecologists to perfor
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth --","length":169,"tagName":"p"},{"type":"text","content":"ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm Insemination Prep Kit, designed to fully enable gynecologists to perform FemaSeed Intratubal Insemination. The kit includes customized components, such as sperm washing for specific use with the FemSperm Setup kit to optimize sperm preparation for FemaSeed procedures.","length":528,"tagName":"p"},{"type":"text","content":"This offering marks a key milestone in advancing Femasys’ gynecology-focused commercialization strategy for the FemaSeed platform and supports entry into the large, underserved fertility market. By providing a streamlined, in-office solution, the company is creating the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, broadening patient access to alternatives ahead of IVF and strengthening its long-term revenue growth strategy.","length":475,"tagName":"p"},{"type":"text","content":"“The availability of the FemSperm Insemination Prep Kit completes the sperm preparation process required for FemaSeed and enables tens of thousands of gynecologists to offer our first-step fertility solution directly within their practices,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “Until now, most gynecologists have lacked a convenient method for sperm preparation. With an estimated 10 million U.S. women facing infertility and only about 200,000 IVF transfer cycles performe...